Clinical Trial Update: Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating ibrutinib in combination with standard immuno-chemotherapy in younger, high-risk adults with diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: University Hospital Muenster | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: COMPLETED